A critical role of the cAMP sensor Epac in switching protein kinase signalling in prostaglandin E2-induced potentiation of P2X3 receptor currents in inflamed rats.
Sensitization of purinergic P2X receptors is one of the mechanisms responsible for exaggerated pain responses to inflammatory injuries. Prostaglandin E2 (PGE2), produced by inflamed tissues, is known to contribute to abnormal pain states. In a previous study, we showed that PGE2 increases fast inactivating ATP currents that are mediated by homomeric P2X3 receptors in dorsal root ganglion (DRG) neurons isolated from normal rats. Protein kinase A (PKA) is the signalling pathway used by PGE2. Little is known about the action of PGE2 on ATP currents after inflammation, although the information is crucial for understanding the mechanisms underlying inflammation-induced sensitization of P2X receptors. We therefore studied the effects of PGE2 on P2X3 receptor-mediated ATP currents in DRG neurons dissociated from complete Freund's adjuvant (CFA)-induced inflamed rats. We found that PGE2 produces a large increase in ATP currents. PKCepsilon, in addition to PKA, becomes involved in the modulatory action of PGE2. Thus, PGE2 signalling switches from a solely PKA-dependent pathway under normal conditions to both PKA- and PKC-dependent pathways after inflammation. Studying the mechanisms underlying the switch, we demonstrated that cAMP-responsive guanine nucleotide exchange factor 1 (Epac1) is up-regulated after inflammation. The Epac agonist CPT-OMe mimics the potentiating effect of PGE2 and occludes the PKC-mediated PGE2 action on ATP currents. These results suggest that Epac plays a critical role in P2X3 sensitization by activation of de novo PKC-dependent signalling of PGE2 after inflammation and would be a useful therapeutic target for pain therapies.
Wang
Congying
C
Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555-1069, USA.
Gu
Yanping
Y
Li
Guang-Wen
GW
Huang
Li-Yen Mae
LY
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism*; D005727:Ganglia, Spinal / Q000378:metabolism; D020662:Guanine Nucleotide Exchange Factors / Q000378:metabolism*; D007249:Inflammation / Q000378:metabolism*; D009619:Nociceptors / Q000378:metabolism*; D051744:Protein Kinase C-epsilon / Q000378:metabolism*; D051381:Rats; D018048:Receptors, Purinergic P2 / Q000378:metabolism; D058477:Receptors, Purinergic P2X3; D015398:Signal Transduction / Q000502:physiology
C482601:Epac protein, mouse; D020662:Guanine Nucleotide Exchange Factors; C546409:P2rx3 protein, mouse; D018048:Receptors, Purinergic P2; D058477:Receptors, Purinergic P2X3; D000255:Adenosine Triphosphate; D017868:Cyclic AMP-Dependent Protein Kinases; D051744:Protein Kinase C-epsilon; D015232:Dinoprostone
Neuron. 1999 Sep;24(1):253-60
10677042
J Physiol. 1997 Dec 1;505 ( Pt 2):503-11
9423189
Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41
9537820
J Neurochem. 1998 Jun;70(6):2606-12
9603227
J Neurosci. 1998 Aug 15;18(16):6081-92
9698303
J Neurosci. 1998 Dec 15;18(24):10345-55
9852572
Science. 1998 Dec 18;282(5397):2275-9
9856955
Br J Pharmacol. 1999 Jan;126(1):326-32
10051152
Eur J Pharmacol. 1999 Feb 12;367(1):33-9
10082262
J Neurophysiol. 1999 Sep;82(3):1590-8
10482772
Physiol Rev. 1999 Oct;79(4):1193-226
10508233
Trends Pharmacol Sci. 2004 Sep;25(9):487-93
15559251
Pain. 2005 Jan;113(1-2):185-90
15621379
J Neurosci. 2005 Jan 5;25(1):208-14
15634783
J Biochem. 2004 Dec;136(6):761-7
15671486
J Neurosci. 2005 Jun 29;25(26):6119-26
15987941
Biochem Soc Trans. 2005 Aug;33(Pt 4):635-8
16042561
Br J Anaesth. 2000 Apr;84(4):476-88
10823099
J Neurosci. 2000 Jun 15;20(12):4680-5
10844037
J Neurosci. 2005 Aug 24;25(34):7734-42
16120774
Mol Pain. 2005;1:26
16159392
Pain. 2005 Dec 15;119(1-3):38-48
16298067
Mol Pharmacol. 2006 Mar;69(3):846-56
16306229
J Biol Chem. 2006 Apr 28;281(17):11805-14
16484231
Biochim Biophys Acta. 2007 Feb;1773(2):166-75
17052768
Mol Pain. 2007;3:22
17692121
J Biol Chem. 2001 May 11;276(19):16083-91
11278900
J Biol Chem. 2001 Jun 15;276(24):21077-82
11264291
J Physiol. 2001 Jul 15;534(Pt. 2):437-45
11454962
J Physiol. 2001 Nov 15;537(Pt 1):115-23
11711566
Nat Cell Biol. 2001 Nov;3(11):1020-4
11715024
J Neurosci. 2002 Jan 1;22(1):93-102
11756492
Pain. 2002 Jan;95(1-2):41-7
11790466
J Neurosci. 2000 Aug 1;20(15):RC90
10899177
Pain. 2002 Apr;96(3):285-96
11973001
Am J Physiol Regul Integr Comp Physiol. 2002 Jun;282(6):R1618-27
12010743
J Neurosci. 2002 Sep 1;22(17):7444-52
12196566
Physiol Rev. 2002 Oct;82(4):1013-67
12270951
Nat Cell Biol. 2002 Nov;4(11):901-6
12402047
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17179-84
12482951
Neuroscience. 2003;120(1):219-26
12849754
Neuron. 2003 Aug 14;39(4):613-24
12925276
Nat Rev Mol Cell Biol. 2003 Sep;4(9):733-8
14506476
Neuroscientist. 2003 Oct;9(5):370-8
14580121
Nat Rev Neurosci. 2004 Feb;5(2):135-45
14735116
J Neurosci. 2004 Jan 21;24(3):642-51
14736850
J Physiol. 2004 Jan 15;554(Pt 2):301-8
12832496
Biochem J. 2004 Aug 15;382(Pt 1):101-10
15144237
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11868-73
15292517
J Biol Chem. 2004 Sep 17;279(38):39485-94
15262999
Endocrinology. 1996 Jun;137(6):2572-9
8641211
Br J Pharmacol. 1995 Dec;116(7):2828-37
8680713
J Neurosci. 1997 Jul 15;17(14):5297-304
9204914
Brain Res. 1997 Oct 24;772(1-2):82-6
9406958
J Biol Chem. 2000 Apr 7;275(14):10190-5
10744703